CARE HK
Study date: 08 December 2022
Status: Open
The purpose of this study is to understand how people with heart failure are treated, especially with regards to a class of medications for heart failure called “renin-angiotensin-aldosterone system inhibitors (RAASi)”. The study compares the given therapy to the treatment recommendations in guidelines from major cardiovascular diseases associations.
RAASi medications are known to have many benefits for heart failure patients. However, RAASi can also cause high blood potassium in some patients (hyperkalaemia), which can be a dangerous condition. The most common treatment for a high blood potassium is to decrease the dose of, or stop RAASi treatment, despite the overall benefits.
This study will investigate the changes to the RAASi medications overall, and after an episode of high blood potassium in patients who have or who are at a high risk of developing hyperkalaemia. The study will also investigate whether patients treated with RAASi according to the treatment guideline recommendations can potentially benefit by living longer, improving the heart failure symptoms, avoiding hospitalisations and avoiding cardiovascular events. Another aim of this study is to evaluate RAASi treatment patterns and effectiveness of patiromer (a drug which reduces potassium levels in patients with hyperkalaemia) in a subgroup of patients who are already being treated with patiromer as part of their regular medical care.
This study is non-interventional, which means you will not receive any medications or treatments as part of the study. You will continue to receive your regular medical care from your doctor. Taking part in the study involves completing an electronic questionnaire about your symptoms and your quality of life upon enrolment and every 6 months until the end of your time on the study. The questionnaire takes about 5 minutes to complete.
To find out more, contact us on nuth.PRCNewcastle@nhs.net.